Key Points- Novo Nordisk will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio. – The deal is Novo Nordisk’s latest attempt to capitalize on the weight loss industry gold rush, which began last year after its Wegovy and Ozempic injections […]
